The association of serum clusterin levels and Clusterin rs11136000 polymorphisms with Alzheimer disease in a Turkish cohort

Gamze Guven; Ebru Ozer; Basar Bilgic; Hasmet Hanagasi; Hakan Gurvit; Ebba Lohmann; Nihan Erginel-Unaltuna

doi:10.4103/NSN.NSN_46_20

Users Online: 183

ORIGINAL ARTICLE

Year : 2020 \| Volume : 37 \| Issue : 3 \| Page : 134-140

The association of serum clusterin levels and Clusterin rs11136000 polymorphisms with Alzheimer disease in a Turkish cohort Gamze Guven¹, Ebru Ozer¹, Basar Bilgic², Hasmet Hanagasi², Hakan Gurvit², Ebba Lohmann³, Nihan Erginel-Unaltuna¹ ¹ Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, TR, Turkey ² Department of Neurology, Istanbul Faculty of Medicine, Behavioural Neurology and Movement Disorders Unit, Istanbul University, Istanbul, TR, Turkey ³ Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen; DZNE, German Center for Neurodegenerative Diseases, Tübingen, GER, Germany Correspondence Address: Gamze Guven Department of Genetics, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul Turkey Source of Support: None, Conflict of Interest: None DOI: 10.4103/NSN.NSN_46_20

Objectives: Several large-scale genome association studies have shown that variants in the “Clusterin”' (CLU) gene are important risk factors for Alzheimer's disease (AD). It has also been shown that plasma CLU levels were elevated in patients with AD and associated with disease severity and progression. In this study, we aimed to investigate whether the CLU rs11136000 polymorphism was associated with AD in our cohort of Turkish patients. We also evaluated the association of serum CLU levels and rs11136000 genotypes between patients and controls. Materials and Methods: Genotyping was performed in 327 patients who were diagnosed as having AD (mean age: 67.2 ± 10.8 years) and 344 controls (mean age: 57.7 ± 13.1 years). The rs11136000 genotypes were determined using quantitative real-time polymerase chain reaction with hydrolysis probes. Serum CLU levels were assessed in 25 patients with AD and 10 controls using enzyme-linked immunosorbent assay. Results: Our results showed no significant difference in genotype and allele frequencies of CLU rs11136000 polymorphisms between patients with AD and controls. Serum CLU levels in patients with AD did not differ from those of the controls. Furthermore, serum CLU levels showed no major difference between carriers of CC and TT + CT genotypes in the controls and patients with AD. Conclusion: Our results suggest that the CLU rs11136000 polymorphism is not associated with AD in our Turkish patients, and rs11136000 genotypes may not have an effect on serum CLU levels.



[FULL TEXT] [PDF]*

Table of Contents

Similar in PUBMED

Search Pubmed for

Search in Google Scholar for

Related articles

Citation Manager

Access Statistics

Reader Comments

Email Alert *

Add to My List *

* Requires registration (Free)

Article Access Statistics

Viewed	2571

Printed	142

Emailed	0

PDF Downloaded	193

Comments	[Add]